Autoimmune myositis (AIM) is a group of diseases affecting skin and muscles in both children and adults. The spectrum of AIM includes polymyositis (PM), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM) and anti-synthetase syndrome (ASS). The prognosis of AIM is largely determined by the presence of concomitant interstitial lung disease (ILD) and cancer. Over the past two decades, great advances have been achieved in the research of AIM. The aberrant distribution and activation of immune cell subtypes, expression of cytokines and myositis specific antibodies (MSAs) have been observed in patients with AIM, suggesting the critical role of autoimmune inflammatory phenomena in the pathogenesis of AIM. Furthermore, genetics, environmental factors, immunometabolism and cell death pathways have also been involved in the pathogenesis of AIM. The detection of MSAs have greatly facilitated the classification of AIM. The treatment strategies stratified by MSAs improved the outcome significantly of patients with AIM, but challenges exist in refractory patients.
The goal of this Research Topic is to provide a forum to advance research on immunological and rheumatological aspects of AIM such as the immunopathogenic mechanisms, genetics, biomarkers, classification and treatments.
We welcome submissions of Original Research, Review, Mini Review, instructive Case Report, Opinion and Clinical Trial with a focus on the clinical and basic studies of AIM, focusing on, but not limited to the following topics:
• studies focusing on the immunopathogenic mechanisms of AIM.
• studies focusing on the genetic background of AIM.
• opinions or studies focusing on the classification of AIM.
• new biomarkers, technologies and predictive algorithms for the evaluation of the severity and progression of DM (or ASS) associated ILD and IMNM.
• novel therapeutic options for DM (or ASS) associated ILD and IMNM (e.g. small molecules, biologics, anti-fibrosis medications, plasma exchange /immunoadsorption, extracorporeal membrane oxygenation, lung transplantation and their combination).
• novel treatment options for skin diseases in DM.
• treatments of juvenile AIM.
Autoimmune myositis (AIM) is a group of diseases affecting skin and muscles in both children and adults. The spectrum of AIM includes polymyositis (PM), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM) and anti-synthetase syndrome (ASS). The prognosis of AIM is largely determined by the presence of concomitant interstitial lung disease (ILD) and cancer. Over the past two decades, great advances have been achieved in the research of AIM. The aberrant distribution and activation of immune cell subtypes, expression of cytokines and myositis specific antibodies (MSAs) have been observed in patients with AIM, suggesting the critical role of autoimmune inflammatory phenomena in the pathogenesis of AIM. Furthermore, genetics, environmental factors, immunometabolism and cell death pathways have also been involved in the pathogenesis of AIM. The detection of MSAs have greatly facilitated the classification of AIM. The treatment strategies stratified by MSAs improved the outcome significantly of patients with AIM, but challenges exist in refractory patients.
The goal of this Research Topic is to provide a forum to advance research on immunological and rheumatological aspects of AIM such as the immunopathogenic mechanisms, genetics, biomarkers, classification and treatments.
We welcome submissions of Original Research, Review, Mini Review, instructive Case Report, Opinion and Clinical Trial with a focus on the clinical and basic studies of AIM, focusing on, but not limited to the following topics:
• studies focusing on the immunopathogenic mechanisms of AIM.
• studies focusing on the genetic background of AIM.
• opinions or studies focusing on the classification of AIM.
• new biomarkers, technologies and predictive algorithms for the evaluation of the severity and progression of DM (or ASS) associated ILD and IMNM.
• novel therapeutic options for DM (or ASS) associated ILD and IMNM (e.g. small molecules, biologics, anti-fibrosis medications, plasma exchange /immunoadsorption, extracorporeal membrane oxygenation, lung transplantation and their combination).
• novel treatment options for skin diseases in DM.
• treatments of juvenile AIM.